129 related articles for article (PubMed ID: 1715768)
1. Cellular source of soluble interleukin 2 receptors in serum of mice after recombinant interleukin 2 administration.
Wagner DK; Wong HL; Gately MK; Nelson DL
Cytokine; 1990 Sep; 2(5):337-43. PubMed ID: 1715768
[TBL] [Abstract][Full Text] [Related]
2. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J
Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
4. Natural cytolytic activity in mice with natural or induced cellular defects. I. Differential ability of in vitro interleukin-2 addition to augment natural cytolytic function.
Ades EW; Hinson A; Butler LD
Cell Immunol; 1986 Aug; 101(1):15-23. PubMed ID: 3527446
[TBL] [Abstract][Full Text] [Related]
5. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells.
Brunda MJ; Tarnowski D; Davatelis V
Int J Cancer; 1986 May; 37(5):787-93. PubMed ID: 2422129
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer cells and aging in mice: significance for defining the precursor cell.
Kawakami K; Bloom ET
Mech Ageing Dev; 1987 Dec; 41(3):229-40. PubMed ID: 2892985
[TBL] [Abstract][Full Text] [Related]
7. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
Gately MK; Anderson TD; Hayes TJ
J Immunol; 1988 Jul; 141(1):189-200. PubMed ID: 3259967
[TBL] [Abstract][Full Text] [Related]
8. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2-induced proliferation of murine natural killer cells in vivo.
Biron CA; Young HA; Kasaian MT
J Exp Med; 1990 Jan; 171(1):173-88. PubMed ID: 1688606
[TBL] [Abstract][Full Text] [Related]
10. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY
Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674
[TBL] [Abstract][Full Text] [Related]
11. Population dynamics of natural killer cells in the spleen and bone marrow of normal and leukemic mice during in vivo exposure to interleukin-2.
Christopher FL; Dussault I; Miller SC
Immunobiology; 1991 Dec; 184(1):37-52. PubMed ID: 1800310
[TBL] [Abstract][Full Text] [Related]
12. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
13. Regulation of guinea-pig immune functions by interleukin 2: critical role of natural killer activity in acute HSV-2 genital infection.
Weinberg A; Basham TY; Merigan TC
J Immunol; 1986 Nov; 137(10):3310-7. PubMed ID: 3021853
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
15. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.
Hinuma S; Naruo K; Ootsu K; Houkan T; Shiho O; Tsukamoto K
Immunology; 1987 Feb; 60(2):173-9. PubMed ID: 3493209
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion.
Anderson TD; Hayes TJ; Gately MK; Bontempo JM; Stern LL; Truitt GA
Lab Invest; 1988 Nov; 59(5):598-612. PubMed ID: 3263543
[TBL] [Abstract][Full Text] [Related]
18. Precursor phenotype of lymphokine-activated killer cells in the mouse.
Salup RR; Mathieson BJ; Wiltrout RH
J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver.
Wiltrout RH; Mathieson BJ; Talmadge JE; Reynolds CW; Zhang SR; Herberman RB; Ortaldo JR
J Exp Med; 1984 Nov; 160(5):1431-49. PubMed ID: 6491601
[TBL] [Abstract][Full Text] [Related]
20. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer.
Wiltrout RH; Boyd MR; Back TC; Salup RR; Arthur JA; Hornung RL
J Immunol; 1988 May; 140(9):3261-5. PubMed ID: 3258894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
